High dose interferon alpha-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  American Journal of Gastroenterology

• Publication date

  1995-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 7847297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High dose interferon treatment in chronic hepatitis C.

  1993cited by this paper
• Treatment algorithms for hepatitis B and C.

  1993cited by this paper
• Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy.

  1993cited by this paper
• Natural course of chronic hepatitis C.

  1993cited by this paper
• Long‐term follow‐up of patients with chronic hepatitis C treated with α‐interferon

  1992cited by this paper
• Can the response to interferon treatment be predicted in patients with chronic active hepatitis C?

  1991cited by this paper
• Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.

  1991cited by this paper
• Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

  1991cited by this paper
• Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

  1991cited by this paper
• Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group.

  1990cited by this paper
• A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.

  1990cited by this paper
• Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment.

  1990cited by this paper
• Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase.

  1990cited by this paper
• Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1989cited by this paper
• Hepatitis C: and miles to go before we sleep.

  1989cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper
• Side Effects of Alpha Interferon

  1989cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Non-A, non-B posttransfusion hepatitis--a decade later.

  1985cited by this paper
• Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features.

  1983cited by this paper
• Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

  1982cited by this paper

• Improvement of human interferon HUIFNalpha2 and HCV core protein expression levels in Escherichia coli but not of HUIFNalpha8 by using the tRNA(AGA/AGG).

  2002cites this paper
• Improvement of human interferon HUIFNα2 and HCV core protein expression levels in Escherichia coli but not of HUIFNα8 by using the tRNAAGA/AGG

  2002cites this paper
• Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.

  2001cites this paper
• Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial

  2001cites this paper
• Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: ®nal results of a prospective randomized trial

  2001cites this paper
• The impact of previous HBV infection on the course of chronic hepatitis C

  2000cites this paper
• Gerinnungsparameter vor und nach einer 6monatigen Interferontherapie bei chronischer Hepatitis C

  1999cites this paper
• Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load.

  1999cites this paper
• Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon‐α in interferon nonresponders with chronic hepatitis C

  1999cites this paper
• Severe exacerbation of asthma: a new side effect of interferon-alpha in patients with asthma and chronic hepatitis C.

  1999cites this paper
• Definition of response to antiviral therapy in chronic hepatitis C.

  1999cites this paper
• Interferon alpha-2b in the treatment of chronic hepatitis C: early experience.

  1998cites this paper
• Comparison among Different Types, Dosages and Duration of Interferon Therapy in Chronic Hepatitis C

  1998cites this paper
• The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial.

  1998cites this paper
• Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C

  1997cites this paper
• Long-Term Efficacy of Interferon-alpha and Ursodeoxycholic Acid in Treatment of Chronic Type C Hepatitis

  1997cites this paper
• Dose increase augments response rate to interferon-α in chronic hepatitis C

  1996cites this paper
• [Interferon-alpha in chronic hepatitis C].

  1996cites this paper
• Interferon and other therapies for hepatitis B and hepatitis C infections.

  1996cites this paper
• Dose increase augments response rate to interferon-alpha in chronic hepatitis C.

  1996cites this paper
• Duration of HCV infection as a predictor of nonresponse to interferon

  1996cites this paper